RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial
This study has been terminated.
(Potential safety issue of second primary malignancies in patients treated with lenalidomide.)
Sponsor:
Christie Hospital NHS Foundation Trust
Collaborators:
Celgene Corporation
Leukemia Research Fund
Information provided by:
Christie Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01127542
First received: May 19, 2010
Last updated: December 2, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | No date given |